Bio-Techne (TECH) net assets (shareholders' equity)
Bio-Techne (TECH) had net assets of $2.11B at the end of fiscal 2026 (June 30, 2026). That is 9.9% higher than the $1.92B of fiscal 2025. Figures as of 19 Nov 2026, 00:02 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Net assets, fiscal 2026
- $2.11B
- Change on fiscal 2025
- +9.9%
- Growth, 5 years
- +6.2% a year
- Growth, 10 years
- +9.1% a year
- Highest on record
- $2.11Bfiscal 2026
- Lowest on record
- $456.48Mfiscal 2009
- Fiscal years on record
- 182009–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Bio-Techne net assets (shareholders' equity), in more detail
Over the five fiscal years to 2026 net assets grew at a compound 6.2% a year; over ten years the rate was 9.1% a year. Across the 18 fiscal years on record (2009–2026), the highest was $2.11B in fiscal 2026 and the lowest $456.48M in fiscal 2009.
Net assets by fiscal year
Bio-Techne net assets (shareholders' equity), year by year
| Fiscal year | Net assets | Change | Year ended |
|---|---|---|---|
| 2026 | $2.11B | 9.9% up | |
| 2025 | $1.92B | 7.3% down | |
| 2024 | $2.07B | 5.2% up | |
| 2023 | $1.97B | 15.6% up | |
| 2022 | $1.70B | 8.9% up | |
| 2021 | $1.56B | 13.2% up | |
| 2020 | $1.38B | 18.5% up | |
| 2019 | $1.17B | 8.0% up | |
| 2018 | $1.08B | 13.6% up | |
| 2017 | $949.63M | 8.0% up | |
| 2016 | $879.28M | 3.8% up | |
| 2015 | $846.94M | 6.5% up | |
| 2014 | $795.27M | 7.8% up | |
| 2013 | $737.54M | 9.4% up | |
| 2012 | $674.44M | 15.1% up | |
| 2011 | $586.12M | 16.8% up | |
| 2010 | $501.79M | 9.9% up | |
| 2009 | $456.48M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.
How to read it
Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.
Bio-Techne, figure by figure
- Bio-Techne market cap
- Bio-Techne revenue
- Bio-Techne earnings
- Bio-Techne earnings per share (EPS)
- Bio-Techne P/E ratio
- Bio-Techne P/S ratio
- Bio-Techne P/B ratio
- Bio-Techne free cash flow
- Bio-Techne operating margin
- Bio-Techne dividend
- Bio-Techne shares outstanding
- Bio-Techne total debt
- Bio-Techne cash on hand
- Bio-Techne total assets
- Bio-Techne total liabilities
- Bio-Techne return on equity (ROE)
- Bio-Techne return on invested capital (ROIC)
Bio-Techne (TECH) overview: price, valuation and scorecardAll health care companies by market value
Bio-Techne net assets (shareholders' equity): questions and answers
What are Bio-Techne's net assets?
Bio-Techne (TECH) had net assets of $2.11B at the end of fiscal 2026 (June 30, 2026). That is 9.9% higher than the $1.92B of fiscal 2025.
What is the growth rate of Bio-Techne's net assets?
Over the five fiscal years to 2026 net assets grew at a compound 6.2% a year; over ten years the rate was 9.1% a year.
What are the highest and lowest net assets figures on record for Bio-Techne?
Across the 18 fiscal years on record (2009–2026), the highest was $2.11B in fiscal 2026 and the lowest $456.48M in fiscal 2009.
How is Bio-Techne's net assets calculated?
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Bio-Techne it is on record here for 18 fiscal years, 2009 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: net assets (shareholders' equity)
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Bio-Techne (TECH) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/TECH/net-assets
Underlying data: the company's filings with the SEC and Yahoo Finance.